Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intermittent Nivolumab in Metastatic Renal Cell Carcinoma
NCT03126331Phase 2Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Aug 2017
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in metastatic renal cell carcinoma (mRCC), sponsored by Case Comprehensive Cancer Center. Started Aug 2017; status: completed.
02
Drugs
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT03126331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03126331.